Tag: study

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA¹ 

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx¹.

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

Saint John, Antigua and Barbuda, June 14, 2025 (GLOBE NEWSWIRE) -- BestOnlineSportsbooks.info, a recognized source for sports betting industry insights, today announced the release of a new report exploring the rising integration of cryptocurrency within U.S. online sportsbooks. This comprehensive study outlines the industry-wide shift toward digital currencies and how it is influencing operational practices, user experience, and platform infrastructure.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025.